Ipamorelin for Health & Longevity

Evidence Review created on 08/07/2026 using AI4L / Opus 5

Also known as: NNC 26-0161, Ipamorelin Acetate

Motivation

Ipamorelin is a synthetic peptide, a chain of five amino acids, designed in the late 1990s to make the pituitary gland release a short pulse of growth hormone. It binds the same receptor as ghrelin, the hormone that signals hunger, but was engineered to be unusually clean: in early animal work it released growth hormone without the surges in stress hormones and other pituitary signals that older compounds of its kind produced.

Growth hormone output falls steadily from early adulthood, and restoring it has drawn interest for decades. The company that created ipamorelin took it into human testing, then redirected it toward restoring bowel function after abdominal surgery; that program closed without approval anywhere. It has since found a second life outside formal medicine, sold as a research chemical or dispensed by clinics that market it for body composition, recovery and longevity.

Because it is now widely sold and used outside formal medicine, this review examines what is known about ipamorelin: how it works, what human and animal studies have measured, its plausible benefits and harms, how it is dosed and monitored in practice, and where its supply and legal standing sit.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Ipamorelin

The dedicated article gives the peptide’s exact sequence, molecular formula and molecular weight alongside its receptor pharmacology, which is useful as a quick structural and mechanistic reference. It also catalogues the compound’s development history and its current unapproved status.

Examine

No Examine article exists for ipamorelin. A direct search of examine.com returns no results for the compound.

Examine’s database is built around dietary supplements and food-derived compounds. Ipamorelin is an injectable, unapproved investigational drug rather than a supplement, and Examine does not typically cover prescription or investigational medications, which explains the absence.

ConsumerLab

No ConsumerLab article exists for ipamorelin. A direct search of consumerlab.com returns no results for the compound.

ConsumerLab tests and reviews retail dietary supplements and consumer health products. Ipamorelin is an injectable, unapproved investigational drug that is not sold as a legal supplement, and ConsumerLab does not typically cover prescription or investigational medications, which explains the absence.

Systematic Reviews

No systematic reviews or meta-analyses for Ipamorelin were found on PubMed as of August 7, 2026.

Mechanism of Action

Ipamorelin is a pentapeptide (a five-amino-acid chain) with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is 2-aminoisobutyric acid and the D-prefixed residues are mirror-image amino acids that resist enzymatic breakdown. It was derived by stripping the central Ala-Trp dipeptide out of growth hormone-releasing peptide 1 (GHRP-1, an early synthetic growth hormone-releasing compound).

Primary target — the ghrelin receptor. Ipamorelin is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a, the cell-surface docking site on pituitary and hypothalamic cells that normally responds to ghrelin, the stomach-derived hunger hormone). Activation triggers a signalling cascade inside pituitary somatotroph cells that releases stored growth hormone (GH, the pituitary hormone that drives tissue growth, repair and fat breakdown). Pharmacological profiling with antagonists confirmed that ipamorelin works through this receptor and not through the growth hormone-releasing hormone receptor (Raun et al., 1998). A conflict of interest applies to much of the primary evidence cited in this review and is worth registering at the outset: the characterization, pharmacokinetic and longitudinal bone growth studies were authored by employees of Novo Nordisk, which owned the molecule, and the gastrointestinal and ferret work was authored or funded by Helsinn, which licensed it; the remaining rodent bone and muscle work came from academic groups in Göteborg and Aarhus. No independent group has replicated the selectivity finding.
Downstream signal. Released growth hormone acts on the liver and peripheral tissues to raise insulin-like growth factor 1 (IGF-1, the circulating growth signal through which most of growth hormone’s anabolic effects are actually carried out) and its carrier protein IGFBP-3 (insulin-like growth factor binding protein 3). IGF-1 is the effector for muscle protein synthesis, bone remodelling and cell proliferation.
Pulsatile rather than continuous. Because ipamorelin acts on the pituitary rather than replacing growth hormone directly, it produces a discrete pulse that decays back to baseline, preserving the body’s negative feedback loops involving somatostatin (the hypothalamic hormone that switches growth hormone release off). Human dosing produced a single episode of growth hormone release peaking about 40 minutes after infusion and declining exponentially to negligible concentrations at every dose tested (Gobburu et al., 1999).
Selectivity — the defining claim. In conscious swine, ipamorelin released growth hormone without significantly changing follicle-stimulating hormone, luteinizing hormone, prolactin, thyroid-stimulating hormone, adrenocorticotropic hormone (ACTH, the pituitary signal that instructs the adrenal glands to make cortisol) or cortisol, even at doses more than 200-fold above the dose producing half-maximal growth hormone release. GHRP-2 and GHRP-6, the older peptides of the same chemical family, raised ACTH and cortisol at comparable growth hormone-releasing doses. This is the single property that distinguishes ipamorelin within its class.
Competing mechanistic accounts. Two mechanistic arguments run against the intervention. First, work in mice showed that growth hormone secretagogues, including ipamorelin, increase body fat, serum leptin and food intake by mechanisms independent of growth hormone itself, meaning receptor activation carries effects that the growth hormone pulse does not explain (Lall et al., 2001). Second, in aging mice, deleting or pharmacologically blocking GHS-R1a — the opposite of what ipamorelin does — improved muscle endurance, mitochondrial function and mitophagy (the clearance of worn-out mitochondria), and reduced markers of sarcopenia (age-related loss of muscle mass and strength) (Kerr et al., 2026). Whether the receptor should be turned up or down for musculoskeletal aging is therefore genuinely unsettled.
Pharmacological properties. In healthy men, ipamorelin showed dose-proportional pharmacokinetics with a terminal half-life of approximately 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady state of 0.22 L/kg. It is a peptide, not a small molecule: it is not a substrate for the cytochrome P450 enzymes (CYP, the liver enzyme family that metabolises most conventional medications, including CYP3A4), and is instead cleared by peptidase cleavage and renal excretion. Preclinical work found ipamorelin’s plasma clearance was five-fold lower than that of GHRP-6, that it was excreted mainly in urine rather than bile, and that 60–80% of an administered dose was recovered intact, indicating moderate metabolic resistance; intranasal bioavailability was approximately 20% (Johansen et al., 1998). Tissue distribution is confined largely to the extracellular compartment; it does not meaningfully cross the blood-brain barrier, and its central effects are exerted at circumventricular sites (the few brain regions that sit outside that barrier) where GHS-R1a is accessible from the circulation.

Historical Context & Evolution

Original intended use. Ipamorelin (development code NNC 26-0161) was synthesised at Novo Nordisk during a medicinal-chemistry program aimed at producing orally bioavailable growth hormone secretagogues. The intended clinical targets were growth failure in children, catabolic states, and osteoporosis — indications where boosting endogenous growth hormone was thought preferable to injecting recombinant growth hormone. The team explicitly framed it as “a very interesting candidate for future clinical development” on the strength of its selectivity (Raun et al., 1998).
The growth hormone and aging thesis. Interest in raising growth hormone for health optimization traces to a 1990 trial in which 12 men aged 61 to 81 received recombinant growth hormone for six months. Lean body mass rose 8.8%, adipose tissue mass fell 14.4%, and average lumbar vertebral bone density rose 1.6%, with skin thickness increasing 7.1% (Rudman et al., 1990). Those findings are real and have never been retracted; what changed is the surrounding evidence.
How the assessment shifted, and why. A later synthesis of 18 randomized study populations comprising 220 growth hormone-treated participants confirmed the body-composition signal — fat mass fell 2.1 kg (95% confidence interval, or CI, the range within which the true value most likely lies: -2.8 to -1.35 kg) and lean body mass rose 2.1 kg (CI 1.3 to 2.9 kg) — but found no change in body weight, bone density or most lipids, and significantly higher rates of soft-tissue swelling, joint pain, carpal tunnel syndrome (compression of the nerve at the wrist causing hand numbness and pain) and gynecomastia (breast tissue growth in men), with more frequent onset of diabetes and impaired fasting glucose (Liu et al., 2007). The change was not that the original findings were wrong; it was that longer follow-up, harder endpoints and adverse-event capture were added, and functional outcomes did not follow the body-composition changes.
Evidence running the other way. Separately, two parallel randomized trials of high-dose growth hormone in prolonged critical illness found in-hospital mortality of 39% versus 20% in the Finnish trial of 247 patients and 44% versus 18% in the multinational trial of 285 patients, a relative risk of death (RR, how many times more likely an outcome is in the treated group than in the comparison group) of 1.9 (CI 1.3 to 2.9) and 2.4 (CI 1.6 to 3.5) respectively (Takala et al., 1999). And a substantial body of comparative endocrinology documents that humans and animals with reduced growth hormone signalling are frequently protected from cancer and diabetes and, in animals, live longer (Aguiar-Oliveira & Bartke, 2019). Neither line settles the question for pulsatile secretagogues at physiological doses, but neither can be set aside.
Ipamorelin’s own trajectory. After human pharmacokinetic work in the late 1990s, Novo Nordisk did not pursue the endocrine indications. Rights moved to Helsinn Therapeutics, which developed the compound for postoperative ileus (a temporary shutdown of bowel movement following abdominal surgery), supported by rodent models showing restored gastric and colonic transit (Venkova et al., 2009; Greenwood-Van Meerveld et al., 2012). A 117-patient Phase 2 study and a 320-patient Phase 2 study followed; the program ended without approval, and ipamorelin has never been approved anywhere for any indication.
The gray-market second life. From the mid-2010s onward, ipamorelin reappeared in doping-control seizures and in direct-to-consumer “research peptide” sales, and became a fixture of clinic protocols marketed for body composition, recovery and longevity — a use pathway with no controlled human data behind it at all.

Expected Benefits

Benefits below are graded on the evidence that exists for ipamorelin specifically, with class-level inferences labelled as such. A dedicated search of PubMed, ClinicalTrials.gov, drug-reference sources and expert clinical commentary was performed for the compound’s full benefit profile before this section was written, and no benefit domain claimed in the clinical or commercial literature was excluded.

High 🟩 🟩 🟩

Acute, Dose-Dependent Growth Hormone Release

Ipamorelin reliably produces a single, discrete pulse of growth hormone in humans. The evidence basis is a dose-escalation clinical pharmacology trial in 40 healthy men, eight per dose level, across five 15-minute infusion rates, in which growth hormone rose at every dose level with dose-proportional exposure and an indirect-response model fitted the concentration-effect relationship well. Corroborating potency and efficacy data exist in rat pituitary cells, anaesthetised rats and conscious swine. This is the only ipamorelin effect for which direct, controlled human evidence exists; it is a pharmacodynamic endpoint, not a clinical outcome, and no trial has connected it to any downstream health measure.

Magnitude: Single growth hormone episode peaking at 0.67 hours across infusion rates of 4.21–140.45 nmol/kg; half-maximal growth hormone stimulation at an ipamorelin concentration of 214 nmol/L; modelled maximal growth hormone production rate 694 mIU/L/h (Gobburu et al., 1999).

Medium 🟩 🟩

Endocrine Selectivity Relative to Older Growth Hormone-Releasing Peptides ⚠️ Conflicted

Ipamorelin’s design goal was to release growth hormone without the collateral endocrine effects of GHRP-2 and GHRP-6, and the specificity testing supports that for the pituitary axes. The evidence basis is controlled hormone profiling in conscious swine at extreme dose multiples, together with the absence of any endocrine adverse-event signal in the human Phase 2 program. The finding is conflicted in two ways: the definitive selectivity data are from swine rather than humans, and the appetite dimension of that selectivity does not hold, since ipamorelin increased food intake, leptin and fat mass in mice through growth hormone-independent routes, and sustained ghrelin-receptor agonism with the oral secretagogue MK-677 raised cortisol in a two-year human trial. Selectivity established for a single intravenous pulse cannot be assumed to persist under chronic subcutaneous dosing.

Magnitude: No significant change in follicle-stimulating hormone, luteinizing hormone, prolactin, thyroid-stimulating hormone, ACTH or cortisol at doses more than 200-fold above the growth hormone half-maximal effective dose in swine, versus clear ACTH and cortisol elevation with GHRP-2 and GHRP-6 at growth hormone-equivalent doses (Raun et al., 1998).

Low 🟩

Gain in Fat-Free Mass Through Sustained Growth Hormone Axis Stimulation

The proposition that raising growth hormone pulsatility increases lean tissue has been tested — but with a different, orally active ghrelin-receptor agonist, not with ipamorelin. In a two-year, double-blind, randomized, placebo-controlled trial in 65 healthy adults aged 60 to 81, MK-677 raised growth hormone and IGF-1 into the young-adult range and increased fat-free mass. No ipamorelin study has measured body composition in humans at all, and the transfer is not clean: MK-677 has a long half-life and sustains IGF-1 continuously, whereas ipamorelin produces a two-hour pulse. Critically, the increase in fat-free mass did not translate into any measurable gain in strength or physical function.

Magnitude: Fat-free mass +1.1 kg (CI 0.7 to 1.5 kg) with MK-677 versus -0.5 kg (CI -1.1 to 0.2 kg) with placebo over 12 months, with no change in measured muscle strength or physical function (Nass et al., 2008).

Deeper Slow-Wave and Rapid Eye Movement Sleep

Growth hormone secretion and slow-wave sleep are physiologically coupled, and a secretagogue given at bedtime plausibly reinforces that coupling. The evidence basis is a small crossover study of the oral secretagogue MK-677 in 8 young and 6 older adults, with overnight sleep-laboratory recording used to confirm the sleep stages. No sleep study of ipamorelin exists in humans or animals, so the inference rests entirely on shared receptor pharmacology; the studies were also very small and short. This is nonetheless the benefit most consistently reported anecdotally by people using ipamorelin.

Magnitude: With 25 mg MK-677 in young adults, approximately 50% longer stage IV sleep and more than 20% more rapid eye movement (REM, the sleep stage in which dreaming is concentrated) sleep versus placebo; in older adults, nearly 50% more REM sleep with reduced REM latency (Copinschi et al., 1997).

Bone Formation and Protection Against Steroid-Induced Bone and Muscle Loss

Three independent rodent studies dosed ipamorelin directly and measured skeletal and muscular endpoints. Ipamorelin increased longitudinal bone growth rate dose-dependently in adult female rats without changing total IGF-1, bone turnover markers or osteoclast counts; it increased bone mineral content in adult female rats, though the gain came from larger bone dimensions rather than higher volumetric density; and in rats given methylprednisolone for three months it restored both calf-muscle contraction force and bone formation at the outer bone surface. All of this is rodent data with no human counterpart, and the bone mineral content gain disappeared once corrected for body weight.

Magnitude: Longitudinal bone growth rate 42 µm/day on vehicle versus 44, 50 and 52 µm/day at 18, 90 and 450 µg/day (p < 0.0001, where p is the probability that a difference this large arose by chance, so smaller values indicate a more reliable finding) (Johansen et al., 1999); approximately four-fold higher rate of bone formation at the outer bone surface with ipamorelin plus glucocorticoid versus glucocorticoid alone (Andersen et al., 2001); bone mineral content increased but the ratio to body weight was unaffected (Svensson et al., 2000).

Faster Return of Gut Motility After Abdominal Surgery ⚠️ Conflicted

This is the only clinical outcome ipamorelin has ever been tested against in a randomized trial. Ghrelin-receptor stimulation speeds transit through the upper and lower gastrointestinal tract, and rodent models of postoperative ileus responded well. The human result was directionally favourable but not statistically significant, and the evidence is conflicted: the larger 320-participant follow-on study has no posted results and the development program was discontinued, which is itself informative. Tolerability in the trial was good, with fewer treatment-emergent adverse events on ipamorelin than on placebo.

Magnitude: Median time from first dose to tolerance of a standardized solid meal 25.3 hours with 0.03 mg/kg intravenous ipamorelin twice daily versus 32.6 hours with placebo in 114 bowel-resection patients (p = 0.15, not significant); treatment-emergent adverse events 87.5% versus 94.8% (Beck et al., 2014).

Speculative 🟨

Reduction in Body Fat ⚠️ Conflicted

Fat loss is, alongside muscle gain, the most heavily marketed reason ipamorelin is sold, and the mechanistic case is genuine: growth hormone is lipolytic (it drives the breakdown of stored fat), and pooled randomized data in healthy older adults show recombinant growth hormone lowering fat mass. The evidence for the secretagogue route runs directly against that, which is why the item is flagged as conflicted: the two-year MK-677 trial found no reduction in total or abdominal visceral fat and a larger increase in limb fat than placebo, while ipamorelin itself raised relative body fat, leptin and food intake in mice through growth hormone-independent routes. No ipamorelin study has measured body composition in any human, so the basis for the marketed fat-loss claim is mechanistic and anecdotal only.

Connective Tissue Repair and Injury Recovery

This is the most commonly marketed use of ipamorelin and has no controlled human or animal evidence behind it for ipamorelin specifically. The mechanistic argument is that growth hormone and IGF-1 support collagen synthesis and tendon remodelling; the only supporting experimental result is improved maximum contraction force in the calf muscles of rats given ipamorelin alongside a glucocorticoid, compared with the glucocorticoid alone. Structured reviews of injectable peptides in sports medicine classify growth hormone axis secretagogues as investigational with uncertain safety and no demonstrated musculoskeletal outcome benefit (Villegas Meza et al., 2026; Mayfield et al., 2026). The basis for this item is therefore mechanistic and anecdotal only.

Reduced Visceral Pain Sensitivity

Ghrelin mimetics attenuated both visceral and somatic nociception (the detection of painful stimuli by the nervous system) in rat models, suggesting an analgesic dimension to GHS-R1a agonism that is independent of growth hormone (Mohammadi et al., 2020). No human study has examined this for ipamorelin, and no controlled data exist; the basis is preclinical and mechanistic only.

Preservation of Body Weight During Chemotherapy

In ferrets, ipamorelin inhibited cisplatin-induced weight loss, as did the related agonist anamorelin (Lu et al., 2024). Anamorelin has been developed clinically for cancer cachexia (severe wasting of muscle and fat in advanced illness), which lends the mechanism plausibility, but ipamorelin itself has never been tested in cancer patients. The basis is a single animal study plus class analogy.

Improved Skin Thickness and Collagen Quality

Skin firmness and thickness are among the most heavily marketed reasons ipamorelin is sold by clinics, and the mechanistic case is that growth hormone and IGF-1 drive type I collagen synthesis in skin and connective tissue. The strongest supporting observation is indirect: recombinant growth hormone increased skin thickness by 7.1% over six months in older men, a change that did not reach conventional statistical significance (Rudman et al., 1990), and the pooled randomized data in healthy older adults did not carry the finding forward as an established outcome (Liu et al., 2007). No ipamorelin study has measured skin thickness, collagen content or any dermatological endpoint in humans or animals, so the basis for the marketed skin claim is mechanistic and anecdotal only.

Enhanced Immune Function

Clinic marketing regularly attributes improved immune resilience to ipamorelin, on the argument that growth hormone and IGF-1 receptors are expressed on lymphocytes and that the growth hormone axis contributes to thymic maintenance. No ipamorelin study has measured any immune endpoint, and the class-level human trial of a ghrelin-receptor agonist did not report immune outcomes. The comparative evidence also runs the other way for the underlying premise, since humans and animals with reduced growth hormone signalling are not characterised by impaired immunity (Aguiar-Oliveira & Bartke, 2019). The basis for this item is mechanistic only, with no controlled or anecdotal human data specific to the compound.

Improved Mental Clarity, Mood, Energy and Libido

Clinics that dispense ipamorelin routinely market sharper cognition, better mood, higher daytime energy and restored libido alongside the physical claims, and the mechanistic argument is that growth hormone and IGF-1 receptors are present in the hippocampus and that the ghrelin receptor itself is expressed in brain regions governing motivation and reward. The only relevant controlled data come from the class rather than the compound: the two-year trial of the oral ghrelin-receptor agonist MK-677 measured quality of life and physical function and found no improvement despite a clear rise in growth hormone and IGF-1 (Nass et al., 2008), and ipamorelin does not meaningfully cross the blood-brain barrier, which limits any direct central action. What subjective improvement users report is at least as easily explained by the deeper sleep described above as by any independent effect on cognition, mood or sexual function. No ipamorelin study has measured a cognitive, mood, energy or libido endpoint in humans or animals, so the basis for these marketed claims is mechanistic and anecdotal only.

Benefit-Modifying Factors

Growth hormone receptor genotype: The exon 3-deleted variant of the growth hormone receptor gene (GHR, the gene encoding the cell-surface protein that growth hormone binds to) produces a receptor isoform with greater signal transduction per unit of growth hormone. Carriers generate more IGF-1 for the same growth hormone pulse, so an identical ipamorelin dose is expected to yield a larger downstream effect — and, symmetrically, a larger IGF-1 excursion to monitor.
Ghrelin receptor and ghrelin-pathway variants: Polymorphisms in GHSR (the human gene encoding GHS-R1a, ipamorelin’s direct target) alter receptor expression and constitutive activity, and variants in FTO (a gene that influences body mass and circulating ghrelin concentrations) shift baseline ghrelin tone. Both plausibly modify responsiveness, though no study has stratified an ipamorelin response by genotype.
Baseline IGF-1 and growth hormone pulsatility: People whose IGF-1 already sits in the upper part of the age-adjusted reference range have limited headroom; the pituitary reserve is finite and the pulse adds proportionally less. Those with genuinely low-normal IGF-1 and blunted overnight pulsatility have the largest theoretical scope for change and are the group in whom class-level body-composition effects were largest.
Baseline body composition: Visceral adiposity suppresses growth hormone secretion and blunts the pituitary response to secretagogues, largely through elevated free fatty acids and insulin. Higher body fat therefore predicts a smaller growth hormone pulse from the same dose, which is the opposite of the pattern most users assume.
Sex-based differences: Women secrete growth hormone with higher pulse amplitude and more continuously than men, yet show relative hepatic resistance to it, so a given growth hormone pulse yields less IGF-1. Oral estrogen amplifies this by suppressing liver IGF-1 generation through first-pass exposure; transdermal estrogen does not. Women on oral estrogen therapy are expected to see the smallest IGF-1 response.
Pre-existing health conditions: Untreated hypothyroidism blunts growth hormone secretion and action; insulin resistance and type 2 diabetes suppress growth hormone pulsatility and simultaneously worsen the metabolic consequences of raising it; chronic kidney disease alters clearance of both the peptide and IGF-1; and untreated obstructive sleep apnea (repeated pauses in breathing during sleep) fragments the slow-wave sleep in which the largest endogenous growth hormone pulse occurs, removing the physiological rhythm a bedtime dose is meant to reinforce.
Age: Growth hormone secretion declines by roughly 10–15% per decade from the third decade onward, so older adults have both the lowest baseline and, in absolute terms, the most to gain. Pituitary somatotrophs remain responsive to secretagogues well into the eighth decade, which is why the class-level body-composition data come from participants aged 60 to 81. At the older end, however, the same physiology that creates the opportunity — reduced reserve, higher visceral fat, more insulin resistance — also compresses the achievable response and widens the adverse-event margin.

Potential Risks & Side Effects

A dedicated search of drug-reference sources, compounding-pharmacy and clinic patient information, regulatory documentation from the U.S. Food and Drug Administration (FDA) and the World Anti-Doping Agency (WADA), doping-control analytical literature, and the 2026 narrative reviews of peptide therapeutics was performed for the full risk profile before this section was written. Because ipamorelin has no prescribing information — it was never approved — several risks below are drawn from the drug class and are labelled accordingly.

High 🟥 🟥 🟥

Absence of Long-Term Human Safety Data

The longest controlled human exposure to ipamorelin on record is the postoperative-ileus programme: seven days of twice-daily intravenous dosing in the 117-patient study that was published, and up to ten days of twice- or three-times-daily intravenous dosing in the 320-patient study whose results were never released. Every other human dataset is single-dose pharmacology. No human has been studied on the subcutaneous, months-long, self-administered regimens that clinics and vendors describe. This is not an absence of evidence of harm at those durations — it is an absence of evidence of any kind. Multiple 2026 reviews converge on this point, characterising growth hormone axis secretagogues as investigational with uncertain safety profiles and no established dosing, frequency or duration (Mendias & Awan, 2026; Villegas Meza et al., 2026).

Magnitude: Maximum controlled human exposure 7 days with published results (0.03 mg/kg intravenously twice daily, 114 patients) and up to 10 days in the unreported 320-patient study (0.03–0.06 mg/kg intravenously two or three times daily); zero human studies of subcutaneous administration at any duration.

Unregulated Supply with Documented Product Substitution

Ipamorelin cannot be obtained from a lawful pharmaceutical source in the United States, so essentially all consumer material comes from research-chemical vendors or overseas manufacturers. Analytical work on seized material found that preparations sold as ipamorelin, GHRP-2, GHRP-6 and modified growth hormone-releasing factor were in every case the glycine-extended analog rather than the labelled peptide — a different molecule with unstudied pharmacology and unknown immunogenicity (Gajda et al., 2019). A parallel investigation of black-market growth-promoting products independently identified Gly-ipamorelin alongside a modified 192-amino-acid growth hormone variant (Krug et al., 2018). Sterility, endotoxin content and residual synthesis solvents are not verified in this supply chain.

Magnitude: In a Danish customs seizure series analysed by high-resolution mass spectrometry, 100% of the examined growth hormone secretagogue powders were N-terminally glycine-extended analogs rather than the peptides named on the label.

Anti-Doping Sanction in Competitive Sport

Ipamorelin is named explicitly on the WADA Prohibited List under class S2, peptide hormones, growth factors, related substances and mimetics, as a growth hormone secretagogue. S2 substances are prohibited at all times, both in and out of competition, and are non-specified, which carries the maximum default sanction. Urinary detection methods for ipamorelin and its metabolites are established and routinely deployed (Thomas et al., 2012), so this is an operational risk, not a theoretical one (The Prohibited List).

Magnitude: Prohibited at all times with no permitted threshold; default sanction for a non-specified S2 anti-doping rule violation is four years of ineligibility.

Medium 🟥 🟥

Insulin Resistance and Rising Fasting Glucose

Growth hormone is a counter-regulatory hormone: it opposes insulin action in muscle and liver, raising hepatic glucose output and reducing peripheral glucose uptake. This is a mechanism-level certainty for the class, and the two-year human secretagogue trial measured it directly. The effect is dose- and duration-dependent, largely reversible on discontinuation, and disproportionately consequential for people who already have impaired fasting glucose or metabolic syndrome. Because ipamorelin’s pulse is short, the total daily glycemic burden should be smaller than with a long-acting agent, but no study has verified that.

Magnitude: Fasting blood glucose rose an average of 0.3 mmol/L (5 mg/dL) with 25 mg/day MK-677 over 12 months (p = 0.015), with a measured decrease in insulin sensitivity (Nass et al., 2008); growth hormone therapy in healthy older adults was associated with more frequent onset of diabetes and impaired fasting glucose (Liu et al., 2007).

Fluid Retention, Joint Pain and Nerve Compression

Growth hormone promotes renal sodium and water retention, which expands extracellular fluid volume and produces peripheral swelling, joint aching, and compression neuropathies at anatomically tight sites — most commonly the median nerve at the wrist. These are the signature dose-limiting effects of growth hormone axis stimulation and appear within weeks. They are reversible with dose reduction or cessation. At sustained supraphysiological exposure the same biology produces the soft-tissue and skeletal changes of acromegaly (the disorder caused by chronic growth hormone excess, with enlargement of the hands, feet and jaw), though no such case has been reported from secretagogue use at studied doses.

Magnitude: Significantly increased rates of soft-tissue edema, arthralgia (joint pain), carpal tunnel syndrome and gynecomastia versus control across 18 randomized study populations totalling 220 growth hormone-treated participants (Liu et al., 2007); transient mild lower-extremity edema and muscle pain were among the most frequent adverse effects in the two-year secretagogue trial.

Increased Appetite, Fat Gain and Weight Gain

Ipamorelin is a ghrelin-receptor agonist, and ghrelin’s primary physiological role is to stimulate appetite. In mice, ipamorelin and GHRP-6 increased relative body fat, serum leptin and food intake, and — importantly — did so in growth hormone-intact animals by mechanisms independent of growth hormone, while growth hormone itself reduced relative fat mass. The commercial framing of ipamorelin as “selective” refers to pituitary hormone spillover, not to appetite, and this distinction is routinely lost. Weight gain in the human secretagogue trial exceeded the lean-mass gain, meaning fat was added as well.

Magnitude: In mice, ipamorelin increased body weight approximately 15% by two weeks and increased fat pad weight relative to body weight (Lall et al., 2001); in humans on MK-677, body weight rose 2.7 kg (CI 2.0 to 3.5) versus 0.8 kg (CI -0.3 to 1.8) on placebo and limb fat rose 1.1 kg versus 0.24 kg (p = 0.001) (Nass et al., 2008).

Cortisol Elevation Under Sustained Receptor Stimulation ⚠️ Conflicted

The evidence here points in two directions and the conflict matters. Acute ipamorelin dosing in swine produced no ACTH or cortisol rise even at extreme dose multiples, which is the compound’s central selling point. But sustained ghrelin-receptor agonism with an orally active agent raised cortisol measurably over 12 months in humans. Whether the discrepancy reflects the molecule, the species, the dosing pattern, or the duration is unresolved, and it cannot be resolved without a chronic human study of ipamorelin, which does not exist. Chronically elevated cortisol would blunt the very anabolic effect the intervention is taken for.

Magnitude: Cortisol rose 47 nmol/L (1.7 µg/dL; CI 28 to 71 nmol/L) with 25 mg/day MK-677 over 12 months (p = 0.020) (Nass et al., 2008), versus no significant ACTH or cortisol change with acute ipamorelin at more than 200-fold the growth hormone half-maximal effective dose in swine (Raun et al., 1998).

Low 🟥

Theoretical Promotion of Occult Neoplasia via IGF-1

IGF-1 is mitogenic (it drives cell division) and anti-apoptotic (it blocks the programmed self-destruction of damaged cells), which is what makes neoplasia (abnormal, uncontrolled cell growth that produces a tumour) the concern here. Observational epidemiology has repeatedly linked higher circulating IGF-1 to prostate, breast and colorectal cancer incidence. No study has linked ipamorelin to any cancer outcome, and pulsatile physiological growth hormone release is not equivalent to the sustained IGF-1 elevation of acromegaly. Contemporary endocrinology reviews of performance-enhancing peptides describe this as a “biologically plausible but unproven mitogenic concern” (Dominikowski et al., 2026). The practical implication is that a person with an undetected malignancy could be supplying growth signal to it without any way of knowing.

Magnitude: Not quantified in available studies.

Injection-Site Reactions and Immunogenicity

Subcutaneous peptide injection carries the usual local risks — erythema (redness), induration (hardening of the tissue), nodule formation, lipoatrophy (a dent where fat under the skin is lost) and infection — compounded here by non-pharmaceutical reconstitution and storage. Beyond local reactions, synthetic peptides can provoke anti-drug antibodies, and impurity profiles in unregulated material raise that risk; immunogenicity and peptide-related impurities are the specific concerns FDA recorded for ipamorelin acetate when it placed the substance in Category 2, noting also that its unnatural amino acids complicate peptide characterisation (Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks). Reported adverse effects for the class include injection-site reactions alongside endocrine and musculoskeletal complaints (Dominikowski et al., 2026).

Magnitude: Not quantified in available studies.

Attenuation of the Pituitary Response with Continued Dosing

Repeated GHS-R1a agonism can desensitize the receptor and deplete the releasable growth hormone pool. The one direct test came in adult female rats dosed three times daily for 15 days: the growth hormone response to a provocative ipamorelin challenge was reduced afterwards, while the response to growth hormone-releasing hormone and total pituitary growth hormone content were unchanged — a pattern consistent with receptor-level rather than pituitary-level attenuation. This is the empirical basis for the cycling schedules used in practice.

Magnitude: Marginally reduced plasma growth hormone response to a provocative intravenous ipamorelin dose after 15 days of dosing (p < 0.03), with unchanged response to growth hormone-releasing hormone and unchanged pituitary growth hormone content (Johansen et al., 1999).

Common Short-Term Adverse Effects

Across clinic protocols, compounding-pharmacy patient information and clinical peptide references, the effects reported most often in the first weeks of use are headache, transient dizziness or lightheadedness shortly after a dose, facial flushing or a sensation of warmth, mild nausea, and short-lived drowsiness or fatigue. The proposed mechanism is the acute growth hormone and ghrelin-receptor pulse itself, which transiently shifts vascular tone, gastric motility and central arousal; the same flushing and transient light-headedness pattern is described for the older peptides of this family. All of these are mild and self-limiting, resolve within hours of a dose or within the first few weeks of use, and typically settle with dose reduction or slower titration. The evidence basis is uncontrolled: the single randomized ipamorelin trial recorded fewer treatment-emergent adverse events on drug than on placebo without itemising these symptoms, so frequency estimates rest on clinical and vendor reporting rather than controlled data.

Magnitude: Not quantified in available studies.

Speculative 🟨

Insulin Release and Glycemic Instability ⚠️ Conflicted

Ipamorelin evoked significant insulin secretion from pancreatic tissue of both normal and streptozotocin-diabetic rats, acting through calcium-channel and adrenergic pathways (Adeghate & Ponery, 2004). This runs opposite to growth hormone’s insulin-antagonist effect, and the net direction in an intact human is unknown. No hypoglycemic event has been reported with ipamorelin in humans; the basis is a single ex vivo animal study.

Acceleration of Aging Biology Through Sustained Growth Hormone and IGF-1 Signalling

Across species, reduced growth hormone signalling is associated with extended lifespan and delayed age-related disease: growth hormone receptor-deficient humans with Laron syndrome (an inherited condition in which the body cannot respond to growth hormone) show near-absence of diabetes and cancer, and growth hormone-deficient mouse strains are among the longest-lived rodents known (Aguiar-Oliveira & Bartke, 2019). Aging research in mice found that blocking, rather than activating, the ghrelin receptor improved muscle function in old animals, though lifespan was unchanged (Kerr et al., 2026). Whether a short daily pulse of growth hormone carries this liability at all is entirely unknown; the basis is mechanistic and comparative only, and it is the single most important unresolved question for anyone using this compound for longevity rather than for a defined deficit.

Risk-Modifying Factors

Growth hormone receptor genotype: The same exon 3-deleted GHR variant that amplifies benefit amplifies risk, producing a larger IGF-1 excursion per unit of growth hormone and therefore a greater burden of fluid retention, joint symptoms and glycemic disturbance at any given dose.
Insulin-pathway and diabetes-risk variants: Carriers of variants associated with reduced beta-cell reserve, such as those in TCF7L2 (a gene strongly linked to type 2 diabetes risk through impaired insulin secretion), have less capacity to compensate for growth hormone-induced insulin resistance and are the group in whom fasting glucose is most likely to drift upward.
Baseline IGF-1: A baseline IGF-1 already at or above the upper limit of the age-adjusted reference range leaves no safe margin; the same dose that is physiological for someone in the lower third of that range pushes such a person into a range where acromegalic soft-tissue effects and mitogenic concerns become substantive rather than theoretical.
Baseline glycemic markers: Fasting glucose above 100 mg/dL, hemoglobin A1c (HbA1c, a measure of average blood glucose over roughly three months) above 5.7%, or an elevated HOMA-IR (a calculation from fasting glucose and insulin that estimates insulin resistance) all identify people for whom the class-level glycemic effect is most likely to become clinically meaningful rather than a laboratory curiosity.
Sex-based differences: Fluid retention, joint pain and carpal tunnel syndrome from growth hormone axis stimulation occur more frequently and at lower doses in women, a pattern documented consistently in recombinant growth hormone trials. Women on oral estrogen have a countervailing protection — reduced hepatic IGF-1 generation — but this comes at the cost of reduced benefit. Men carry the specific risk of gynecomastia.
Pre-existing health conditions: Any prior or active malignancy converts the theoretical IGF-1 mitogenic concern into a concrete one. Diabetes and prediabetes magnify glycemic risk. Untreated obstructive sleep apnea can be worsened by growth hormone-driven soft-tissue expansion in the upper airway. Active proliferative diabetic retinopathy (the advanced stage of diabetic eye disease in which fragile new blood vessels grow across the retina) is a recognised contraindication to growth hormone axis stimulation because IGF-1 is angiogenic (it drives the formation of new blood vessels). Heart failure and chronic kidney disease amplify the consequences of sodium and water retention.
Age: Older adults carry higher background prevalence of undiagnosed malignancy, impaired glucose tolerance, and joint pathology, so the same absolute IGF-1 rise lands on a more vulnerable substrate. At the same time, tolerance of growth hormone is dose-dependent and older participants in recombinant growth hormone trials experienced adverse events at doses younger participants tolerated, which is why dose escalation in this group proceeds more slowly than in younger adults.

Key Interactions & Contraindications

Insulin and insulin secretagogues (insulin glargine, glipizide, glyburide, repaglinide): Caution with active monitoring. Growth hormone opposes insulin action, so glycemic control may deteriorate and antidiabetic dose requirements may rise; the opposing preclinical signal for direct insulin release makes the net direction unpredictable in any individual. Mitigation: continuous or frequent glucose monitoring for the first four weeks and again after any dose change.
Glucocorticoids (prednisone, dexamethasone, methylprednisolone, budesonide): Caution, bidirectional. Glucocorticoids suppress growth hormone secretion and antagonise its anabolic action at the tissue level, blunting the intervention; conversely, animal data show ipamorelin partially offsets glucocorticoid-induced bone and muscle loss. Mitigation: a reduced effect is expected during steroid courses, and dose escalation to compensate is counterproductive.
Somatostatin analogs (octreotide, lanreotide, pasireotide): Absolute pharmacodynamic antagonism. These agents suppress pituitary growth hormone release directly and will abolish the effect of a secretagogue. Concurrent use is pointless rather than dangerous, but signals an underlying condition — usually acromegaly or a neuroendocrine tumour — for which growth hormone stimulation is contraindicated.
Recombinant growth hormone (somatropin) and other growth hormone axis agents (tesamorelin, sermorelin, CJC-1295, ibutamoren/MK-677, GHRP-2, GHRP-6, hexarelin): Caution, additive. Stacking multiplies IGF-1 exposure and the associated fluid, glycemic and mitogenic risks without any evidence of additive benefit in humans. Mitigation: one agent at a time; where a growth hormone-releasing hormone analog is combined with a secretagogue, both doses are reduced.
Oral estrogens (conjugated equine estrogens, ethinylestradiol) and selective estrogen receptor modulators (tamoxifen, raloxifene): Caution, effect-reducing. First-pass hepatic exposure to oral estrogen suppresses IGF-1 generation, substantially reducing the downstream signal. Mitigation: transdermal estradiol avoids the interaction, and IGF-1 results are interpreted in light of the route used.
Thyroid hormone (levothyroxine, liothyronine): Monitor. Growth hormone increases peripheral conversion of thyroxine to triiodothyronine and can unmask marginal central hypothyroidism. Mitigation: thyroid-stimulating hormone and free thyroxine at baseline and at 12 weeks.
Glucagon-like peptide-1 (GLP-1, a gut hormone that signals fullness after eating) receptor agonists (semaglutide, tirzepatide, liraglutide): Caution, opposing. These slow gastric emptying and suppress appetite, while ghrelin-receptor agonism does the reverse; the combination produces unpredictable appetite and gastrointestinal effects and confounds interpretation of body-composition changes. Mitigation: trials of the two agents are separated in time rather than combined.
Over-the-counter high-dose niacin (immediate- or extended-release nicotinic acid, 500 mg and above): Caution. Pharmacological niacin independently raises fasting glucose and insulin resistance, compounding the growth hormone effect. Mitigation: nicotinamide or inositol hexanicotinate serves as a substitute, otherwise glucose monitoring is intensified.
Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen): Caution, additive. Both promote renal sodium and water retention, so peripheral swelling and blood pressure elevation may be amplified. Mitigation: acetaminophen is the preferred alternative during the first weeks; most other over-the-counter agents, including antihistamines, proton pump inhibitors and decongestants, have no known interaction.
Supplements with additive growth hormone-releasing effects (L-Arginine 5–9 g, L-Ornithine 2–6 g, glycine 3–6 g, alpha-GPC 600 mg, gamma-aminobutyric acid 3 g, melatonin 0.5–5 mg): Caution, additive. Each of these has been shown to augment growth hormone release, arginine principally by suppressing somatostatin. Mitigation: these count as part of the total growth hormone stimulus and are not added while a dose is being established.
Supplements that oppose the glycemic effect (berberine 500 mg three times daily, chromium picolinate, myo-inositol, alpha-lipoic acid): Generally favourable but requires monitoring. These improve insulin sensitivity and may offset the growth hormone-driven drift in fasting glucose, but they also mask it, so laboratory monitoring is not relaxed on that basis.
Creatine monohydrate: Minor, additive. Creatine causes intracellular water retention that can compound the extracellular fluid retention of growth hormone axis stimulation, making swelling harder to attribute. Mitigation: creatine is held during the first four weeks so that fluid-related symptoms can be interpreted.
Other interventions — fasting, resistance training, sleep restriction and alcohol: Monitor, bidirectional. Prolonged fasting and high-intensity or resistance exercise are themselves potent physiological growth hormone stimuli and are additive; sleep restriction and evening alcohol suppress the overnight growth hormone pulse and will blunt the intervention. Mitigation: dosing occurs in the fasted state, and sleep is protected rather than the dose escalated.
Populations who should avoid this intervention: Active malignancy or any cancer treated within the past 5 years; active proliferative diabetic retinopathy; poorly controlled diabetes (HbA1c above 8.0%); known acromegaly or any functioning pituitary adenoma; untreated severe obstructive sleep apnea (apnea-hypopnea index of 30 or greater); prolonged critical illness or intensive-care admission, where high-dose growth hormone approximately doubled mortality; New York Heart Association Class III or IV heart failure and chronic kidney disease stage 4 or 5, where sodium and water retention is poorly tolerated; pregnancy and lactation; adolescents with open epiphyseal growth plates; and any athlete subject to the WADA Prohibited List or an equivalent national or federation anti-doping code.

Risk Mitigation Strategies

Independent identity and purity verification before first use: A sample from each vial lot is sent to a third-party analytical laboratory for mass-spectrometric identity confirmation and purity quantification, with a target of at least 98% purity and explicit exclusion of the N-terminal glycine-extended analog. This directly addresses the documented product-substitution risk, in which every seized secretagogue preparation in one analytical series proved to be a different molecule than labelled.
Baseline metabolic and malignancy screening before initiation: Fasting glucose, fasting insulin, HbA1c, IGF-1, IGFBP-3, a complete metabolic panel and age-appropriate cancer screening (colonoscopy per standard interval, prostate-specific antigen for men aged 40 and over, mammography for women aged 40 and over) are obtained within 6 months of starting. This screens for the two risks that are both consequential and silent: glycemic deterioration and pre-existing occult neoplasia that IGF-1 elevation could feed.
Lowest effective dose with a defined ceiling on IGF-1: Dosing begins at the low end of the practised range (100 µg once daily) and escalates no faster than every 2 weeks, targeting an IGF-1 that remains within the age- and sex-adjusted reference range and never exceeds the upper limit of normal. Holding IGF-1 inside the physiological range is the single most direct control on fluid retention, joint symptoms, carpal tunnel syndrome and mitogenic exposure.
Structured glycemic surveillance: Fasting glucose and insulin are rechecked at 4 weeks and 12 weeks, and a 14-day continuous glucose monitor at baseline and again at 12 weeks adds resolution. The stopping threshold applied in practice is a fasting glucose above 100 mg/dL or an HbA1c above 5.7% in someone previously below those values. This mitigates the insulin resistance and rising fasting glucose documented for the drug class.
Fasted bedtime administration with a carbohydrate-free window: The dose falls at least 2 hours after the last meal, with carbohydrate deferred for 30–60 minutes afterwards, because elevated insulin and glucose suppress the growth hormone pulse through somatostatin. This both preserves efficacy at a lower dose and reduces the total glycemic load applied alongside a counter-regulatory hormone.
Planned cycling with washout: Continuous use is capped at 8–12 weeks followed by a 4-week interruption, or run as a 5-days-on, 2-days-off weekly pattern. This addresses the receptor-level attenuation of the growth hormone response observed after 15 days of continuous dosing in rats, and provides a scheduled interval at which accumulated benefit and adverse effects can be assessed against baseline.
No stacking during the assessment period: Ipamorelin is taken alone rather than in combination with a growth hormone-releasing hormone analog or another secretagogue for at least the first cycle. Combination protocols multiply IGF-1 exposure and its associated fluid, glycemic and mitogenic risks, and make it impossible to attribute either benefit or harm.
Aseptic reconstitution and cold-chain discipline: Reconstitution is done with bacteriostatic water and a fresh sterile needle for each injection, with refrigeration at 2–8 °C afterwards and disposal within 30 days. This addresses the injection-site infection and contamination risk created by non-pharmaceutical supply and by user reconstitution.
Symptom-triggered stopping rules: Use is halted and reassessed on the appearance of persistent hand or finger numbness, morning hand stiffness, new peripheral swelling that does not resolve within a week, or joint pain — the recognised early signals of excess growth hormone axis stimulation, which are reversible if acted on promptly and progressive if ignored.
Physician supervision and disclosure: Any trial runs under a clinician who knows the full medication list and orders the laboratory panel, with the use recorded in the medical record. This mitigates the interaction risks with insulin, glucocorticoids, thyroid hormone and estrogen therapy, and ensures that a rising IGF-1 or fasting glucose is interpreted by someone who can act on it.

Therapeutic Protocol

No protocol for ipamorelin has been validated in a human trial for any health or longevity endpoint. What follows describes what is actually done in practice, alongside the only regimens that have human data behind them, so the gap between the two is visible.

Standard clinic protocol: The regimen used across peptide-therapy clinics runs from 100 µg at the low end of the practised range to 300 µg, with 200–300 µg the most commonly quoted dose, administered subcutaneously once to three times daily, most commonly as a single bedtime injection, in blocks of 8–12 weeks. The template is disseminated principally through the clinical peptide-training curricula associated with William Seeds and through the peptide-certification programmes of the American Academy of Anti-Aging Medicine (an organization whose members derive direct revenue from the certification fees and the clinic protocols it endorses, so its dosing template is not a disinterested source), and is reproduced by cash-pay hormone and longevity practices. Injection sites are rotated across the abdomen and thigh. Doses are typically expressed in micrograms because vials are supplied as 2 mg or 5 mg of freeze-dried powder reconstituted with bacteriostatic water.
Regimens with actual human data: The only ipamorelin doses ever administered to humans under controlled conditions were intravenous: infusions of 4.21–140.45 nmol/kg over 15 minutes in a dose-escalation pharmacology study, 0.03 mg/kg twice daily by intravenous infusion for up to 7 days in the published Phase 2 postoperative-ileus study, and 0.03–0.06 mg/kg two or three times daily by intravenous infusion for up to 10 days in the larger, unreported Phase 2 study. Neither route nor duration corresponds to what is used in practice, and no dose-response relationship has been established for subcutaneous administration.
Competing approach — growth hormone-releasing hormone analogs: Sermorelin, tesamorelin and CJC-1295 act on a different pituitary receptor to raise growth hormone. The case for this route in age-management practice was set out by Richard F. Walker, whose argument that a releasing-hormone analog is preferable to injected growth hormone because it preserves pituitary feedback (Walker, 2006) became the standard rationale adopted by physician-run longevity clinics. Tesamorelin is the only agent in this family with FDA approval (for excess abdominal fat in lipodystrophy — an abnormal redistribution of body fat — associated with human immunodeficiency virus, or HIV, infection), which makes it the option with a genuine regulatory dossier. Advocates of this route argue it preserves feedback regulation more faithfully; advocates of secretagogues argue the ghrelin-receptor route produces larger pulses. Neither claim has been tested head to head for a longevity endpoint.
Competing approach — combination protocols: The most widely promoted regimen pairs ipamorelin 200–300 µg with CJC-1295 without drug affinity complex (also called modified growth hormone-releasing factor 1-29) at 100 µg, on the rationale that stimulating both receptors produces a supra-additive pulse. The only experimental support is rodent work in glucocorticoid-induced muscle loss. This approach was popularised largely through the peptide-therapy education channel associated with William Seeds, whose work also appears in the orthopaedic literature (Rahman et al., 2026); that overlap between authorship and commercial peptide education is a conflict of interest bearing on protocol recommendations from this quarter.
Competing approach — documented deficiency treatment: For adults with biochemically confirmed growth hormone deficiency, recombinant growth hormone replacement is an approved, dose-titrated therapy with decades of registry data. It is the one route into this physiology that carries regulatory approval and long-term registry data, and it targets a documented deficit rather than an age-related decline, so both its evidence base and its indication differ from those of the approaches above. Institutional payers gatekeep it tightly because it is expensive, which creates a structural incentive favouring cheaper unapproved alternatives that is worth naming explicitly.
Competing approach — non-pharmacological optimization: Slow-wave sleep consolidation, resistance training, high-intensity intervals and extended overnight fasting are each established physiological growth hormone stimuli with no supply, legal or safety liability. Practitioners across the spectrum, including Peter Attia and Life Extension, position these as the appropriate first-line approach; both note the absence of clinical outcome evidence for secretagogues.
Best time of day: Bedtime, on an empty stomach, to coincide with and reinforce the largest endogenous growth hormone pulse of the 24-hour cycle, which occurs during the first episode of slow-wave sleep. A second option used by some practitioners is post-exercise dosing, on the rationale that exercise already opens a growth hormone window. Morning dosing is the least favoured because daytime insulin and glucose excursions suppress the pulse.
Expected half-life: Approximately 2 hours terminal half-life in humans, with dose-proportional kinetics, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The practical implication is that a single dose produces one discrete pulse and no accumulation between daily doses.
Single versus split dosing: A single bedtime dose is the most common pattern and aligns with the physiological rhythm. Two-to-three times daily dosing is used by those prioritising total daily growth hormone exposure, on the argument that a 2-hour half-life means one dose covers only a fraction of the day. The trade-off is direct: more frequent dosing raises cumulative IGF-1 exposure and, by extension, the fluid, glycemic and mitogenic risks, and more closely approximates the continuous stimulation pattern under which cortisol elevation and receptor attenuation have been observed.
Genetic polymorphisms influencing dose: Carriers of the exon 3-deleted GHR variant generate more IGF-1 per unit of growth hormone and reach any given IGF-1 target at a lower dose. Variants in GHSR and in FTO plausibly alter receptor responsiveness and baseline ghrelin tone. No pharmacogenetic dosing algorithm exists; in practice IGF-1 measurement substitutes for genotyping, since it captures the net effect of all of these.
Sex-based differences in dosing: Women require a higher growth hormone stimulus to achieve the same IGF-1 because of relative hepatic growth hormone resistance, but simultaneously experience fluid retention and joint symptoms at lower doses, which narrows the usable window. Women on oral estrogen sit at the extreme of this pattern. Titration by IGF-1 response rather than by fixed microgram amounts is the standard accommodation.
Age-related considerations: Older adults have the lowest baseline growth hormone output and the largest theoretical scope for change, but also the least tolerance for the fluid and glycemic effects. Practitioners typically start at half the usual dose beyond age 65 and escalate at half the usual rate, targeting the mid-range rather than the upper limit of the age-adjusted IGF-1 reference interval.
Baseline biomarkers influencing response: Baseline IGF-1 determines both how much room exists and how much risk any increment carries; baseline fasting insulin and visceral fat predict a blunted growth hormone pulse; and baseline thyroid status determines whether the growth hormone signal can be translated peripherally at all. Each is established before the first dose rather than inferred afterwards.
Pre-existing conditions influencing response: Untreated hypothyroidism, insulin resistance, obesity and fragmented sleep all attenuate the response, and correcting them frequently produces a larger change in growth hormone physiology than the peptide does. Chronic kidney disease alters clearance of both the peptide and IGF-1, warranting lower doses and more frequent measurement.

Discontinuation & Cycling

Intended duration of use: Ipamorelin has never been framed, even by its developers, as a lifelong therapy. Every human exposure on record is measured in days. Clinic practice treats it as an episodic intervention delivered in 8–12 week blocks with defined interruptions, not as chronic replacement therapy, and there is no dataset supporting continuous use beyond a few months.
Withdrawal effects: No withdrawal syndrome has been documented. With a terminal half-life of approximately 2 hours and no evidence of hypothalamic-pituitary suppression — pituitary growth hormone content was unchanged after 15 days of dosing in rats, and the growth hormone-releasing hormone response was preserved — endogenous growth hormone secretion returns to baseline within days. What does reverse is the effect: appetite normalises, fluid retention resolves within 1–2 weeks, and IGF-1 returns to pre-treatment values. Any accrued lean mass is likely to be lost over subsequent months without continued training and adequate protein intake, as it is after recombinant growth hormone withdrawal.
Tapering protocol: No taper is required pharmacologically, and none is described in any protocol. A stepwise reduction over 1–2 weeks is sometimes used to make the distinction between drug effect and placebo effect easier to observe, but there is no physiological basis for it.
Cycling to maintain efficacy: Cycling is standard practice and has a defensible empirical rationale. After 15 days of three-times-daily ipamorelin in rats, the growth hormone response to a provocative dose was reduced while the growth hormone-releasing hormone response and pituitary hormone content were unchanged, pointing to receptor-level attenuation that a washout should reverse. The two common patterns are 8–12 weeks on followed by 4 weeks off, and a weekly 5-days-on, 2-days-off schedule. Neither has been compared to continuous dosing in humans; the schedules are inferred, not validated.
Use of the washout as an assessment window: A scheduled interruption serves a second purpose beyond receptor recovery: it is the only practical way to distinguish a real effect from expectation, since it allows sleep quality, recovery, body composition and laboratory markers to be measured off-drug and compared with on-drug values from the same person.

Sourcing and Quality

No lawful pharmaceutical source exists in the United States: Ipamorelin is not an FDA-approved drug and has never appeared in Category 1 of the section 503A bulk drug substances list, the register that governs which raw substances traditional compounding pharmacies may legally use. Ipamorelin acetate was placed in Category 2 — substances FDA has identified as raising significant safety risks — on 29 September 2023, on the grounds of immunogenicity risk from aggregation and peptide-related impurities, unnatural amino acids that complicate characterisation, and serious adverse events including death reported when it was given intravenously for gastric motility (Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks). It was one of four peptides at issue in the Evexias and Farmakeio litigation against FDA, and the 503A nomination was subsequently withdrawn by the nominators; withdrawal did not make it compoundable, and FDA’s current listing still carries ipamorelin acetate in Category 2 under the 503B interim policy. Formal review of the 503A nomination took place on 29 October 2024, when FDA’s Pharmacy Compounding Advisory Committee considered ipamorelin acetate and ipamorelin free base and voted against adding either to the 503A list, consistent with FDA’s own recommendation (October 29, 2024: Meeting of the Pharmacy Compounding Advisory Committee). It was not among the peptides FDA referred to that committee for the July 2026 review or the review scheduled before the end of February 2027 (FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know).
The practical supply chain is research-chemical vendors: Because no regulated route exists, material is bought from vendors selling “for research use only” freeze-dried powder, typically in 2 mg, 5 mg or 10 mg vials, manufactured predominantly in China and repackaged. These sellers operate outside pharmaceutical current good manufacturing practice and are not subject to identity, potency, sterility or endotoxin requirements. Advocacy from the Alliance for Pharmacy Compounding and from compounding pharmacies for broader peptide access carries a direct commercial interest: their member pharmacies would derive direct revenue from a regulatory change that made these substances dispensable.
Documented substitution is the dominant quality problem: The concrete failure mode is not weak product but a different molecule. High-resolution mass spectrometry of seized preparations labelled as ipamorelin, GHRP-2, GHRP-6 and modified growth hormone-releasing factor found that in every case the material was the N-terminally glycine-extended analog, and independent analysis of black-market growth-promoting products identified Gly-ipamorelin alongside a 192-amino-acid growth hormone variant. Neither analog has been characterised pharmacologically or toxicologically.
What to look for in a certificate of analysis: A meaningful certificate of analysis (CoA, the laboratory document stating a batch’s identity and purity) names the testing laboratory, is dated and lot-specific, reports purity by high-performance liquid chromatography with the chromatogram included, confirms identity by mass spectrometry against the expected mass of 711.9 daltons, and reports water content, residual trifluoroacetic acid from synthesis, bacterial endotoxin and sterility. Vendor-supplied certificates that lack a chromatogram, a lot number or a named laboratory carry no information.
Independent third-party testing is the only real control: Analytical laboratories such as Janoshik Analytical and Colmaric Analyticals accept consumer-submitted samples for identity and purity testing, and community-organised batch testing through these services is currently the only practical verification available to a buyer. Testing each new lot rather than each new vendor is the relevant unit, since lot-to-lot variation within a single vendor is well documented.
Formulation and storage: Ipamorelin is supplied freeze-dried and is stable at room temperature in that state for limited periods, but is stored refrigerated at 2–8 °C and protected from light. Reconstitution with bacteriostatic water, which contains 0.9% benzyl alcohol, permits multi-dose use for approximately 30 days refrigerated; reconstitution with sterile water without preservative requires same-day use. Repeated freeze-thaw cycles degrade the peptide.
Compounding pharmacies as a category: Where a peptide is lawfully compoundable, a 503A pharmacy or 503B outsourcing facility registered with FDA and inspected for sterile preparation is the appropriate source, and state board licensure plus a current inspection record are the relevant credentials to check. Ipamorelin does not currently qualify under either pathway in the United States, so any clinic or pharmacy offering it is operating outside that framework regardless of how it is presented.

Practical Considerations

Time to effect: The growth hormone pulse itself occurs within about 40 minutes of a dose. Subjective changes in sleep depth are the earliest reported effect, typically within the first week, though no controlled data confirm this for ipamorelin. IGF-1 shifts measurably over 1–2 weeks and is the appropriate marker for confirming a biological effect. Body-composition change, by analogy with the class, requires 6–12 months to become measurable and did not translate into strength or function even then.
Common pitfalls: Dosing after a meal or with carbohydrate, which suppresses the pulse through insulin and somatostatin and wastes the dose; assuming that “selective” means appetite-neutral, when it refers only to pituitary hormone spillover; stacking two or three growth hormone axis agents at once, which multiplies risk without demonstrated additive benefit and makes attribution impossible; escalating dose in pursuit of a subjective effect rather than titrating to a measured IGF-1 target; using unverified material without lot testing; and omitting glucose monitoring, since the glycemic drift is silent and is the most likely adverse effect to actually occur.
Regulatory status: Ipamorelin is not approved by FDA, the European Medicines Agency or any other regulator for any indication, and has no prescribing information. It is not a dietary supplement and cannot lawfully be marketed as one. It sits outside the section 503A compounding pathway, having never been in Category 1, and the Pharmacy Compounding Advisory Committee voted in October 2024 against adding it. It is explicitly named on the WADA Prohibited List under class S2 as prohibited at all times. Sale is generally conducted under “research use only” labelling, a designation that does not confer lawful status for human use, and possession or importation for personal use occupies an enforcement gray zone that differs by jurisdiction.
Cost and accessibility: The compound itself is inexpensive relative to recombinant growth hormone, which is the principal reason it has displaced it in cash-pay clinics; the real barrier is not price but the absence of any lawful, quality-assured supply. Clinic programs bundle the peptide with consultation and laboratory work at substantially higher cost, and none of it is reimbursed by insurance or national health systems. That asymmetry is worth naming: institutional payers strictly gatekeep recombinant growth hormone because of its expense, which creates a systematic financial incentive favouring cheap unapproved alternatives in the cash-pay market and shapes which options patients are offered. That incentive is also a potential source of structural bias upstream of the clinic — the same payers and the public bodies that share their cost exposure fund the trials and sit on the committees that write growth hormone axis guidelines, so restrictive prescribing criteria and the near-absence of publicly funded outcome trials in age-related growth hormone decline cannot be read as purely evidentiary judgements.

Interaction with Foundational Habits

Sleep: Direct and bidirectional, and the most important of the four. The largest endogenous growth hormone pulse occurs during the first episode of slow-wave sleep, so sleep restriction or fragmentation blunts the very physiology ipamorelin is meant to reinforce, and dosing into fragmented sleep wastes much of the effect. In the other direction, ghrelin-receptor agonism appears to deepen sleep: the oral secretagogue MK-677 increased stage IV sleep by roughly 50% and REM sleep by more than 20% in young adults, and increased REM sleep by nearly 50% in older adults. Practically, this argues for bedtime dosing and for treating obstructive sleep apnea before rather than during a trial, since growth hormone-driven soft-tissue expansion can worsen upper-airway obstruction.
Nutrition: Direct and blunting in one direction, potentiating in the other. Elevated glucose and insulin suppress growth hormone release through somatostatin, so a dose taken within 2 hours of a meal — particularly a carbohydrate-containing one — produces a substantially smaller pulse. Free fatty acids from a very high-fat meal have the same suppressive effect. Conversely, adequate protein intake is required for any anabolic signal to be translated into tissue, and specific amino acids potentiate the release directly: L-Arginine suppresses somatostatin and augments the growth hormone response, and glycine and L-Ornithine act similarly. The practical pattern is a fasted dose at least 2 hours after eating, with carbohydrate deferred 30–60 minutes afterwards, and daily protein sufficient to support the anabolic signal.
Exercise: Direct and additive, with no evidence of blunting. Resistance training and high-intensity intervals are themselves potent growth hormone stimuli, and there is no mechanism by which a secretagogue would interfere with training adaptation — unlike, for example, high-dose antioxidants. Because the growth hormone axis mediates connective-tissue remodelling, exercise supplies the mechanical signal that determines where any anabolic effect is directed; without training, the class-level evidence shows added mass without added strength or function. Post-exercise dosing is used by some practitioners on the argument that it lands in an already-open window, though bedtime dosing has the stronger physiological rationale.
Stress management: Indirect and antagonistic. Chronically elevated cortisol suppresses growth hormone secretion, opposes its anabolic action at the tissue level, and drives the same visceral fat accumulation and insulin resistance that blunt the growth hormone response — so unmanaged chronic stress works against the intervention from three directions simultaneously. Ipamorelin’s distinguishing feature is that, unlike the older peptides of its family, acute dosing did not raise ACTH or cortisol in specificity testing; whether that holds under months of use is unresolved, since sustained agonism with a related compound did raise cortisol in humans. Practically, this makes cortisol worth measuring rather than assuming, and makes sleep, training load management and recovery practices part of the protocol rather than adjacent to it.

Monitoring Protocol & Defining Success

Before any dose is taken, a baseline panel establishes both whether there is room to raise the growth hormone axis at all and whether the conditions that make doing so hazardous are present. It is drawn fasting, in the morning, within 4 weeks of starting, and paired with age-appropriate cancer screening that is current within 6 months. Without a baseline, neither benefit nor harm can subsequently be attributed.

Ongoing monitoring follows a defined cadence: the core panel is repeated at 4 weeks after initiation, again at 12 weeks or at the end of the first cycle, and thereafter every 3–6 months for as long as use continues. Any dose escalation resets the clock and calls for a repeat panel 4 weeks later.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
IGF-1	Mid-range of the age- and sex-adjusted reference interval; never above the upper limit	Confirms the peptide is producing a real biological effect and caps mitogenic exposure	Insulin-like growth factor 1. Non-fasting is acceptable; the same laboratory is used throughout, as inter-assay variation is large. Oral estrogen lowers it independently of dose
IGFBP-3	Upper half of the reference range	Interprets IGF-1 by indicating how much is bioavailable rather than protein-bound	Insulin-like growth factor binding protein 3. Best paired with IGF-1 in the same draw; a rising IGF-1 with flat IGFBP-3 indicates a larger free fraction than the total suggests
Fasting glucose	75–90 mg/dL	Detects the counter-regulatory glycemic drift that is the most likely adverse effect	Requires a 10–12 hour fast. Conventional laboratories flag only above 100 mg/dL; the functional threshold for concern is lower. The draw is taken before the morning dose if dosing more than once daily
Fasting insulin	2–5 µIU/mL	Detects insulin resistance well before fasting glucose moves	Same draw as fasting glucose; conventional reference ranges extend to 25 µIU/mL, far above the functional target
HOMA-IR	Below 1.0	Single summary index of insulin sensitivity, the metabolic variable most at risk	Homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin. Conventional cut-offs for “insulin resistance” sit at 2.5–2.9; the functional target is considerably tighter
HbA1c	4.8–5.3%	Captures cumulative glycemic drift that spot fasting values can miss	Hemoglobin A1c. Conventional laboratories treat anything below 5.7% as normal, well above the functional target. Reflects roughly 3 months, so it is informative at the 12-week point rather than at 4 weeks. Falsely low with shortened red cell lifespan
Fasting lipid panel with ApoB	ApoB below 80 mg/dL; triglycerides below 80 mg/dL	Growth hormone alters lipolysis and lipid handling; triglycerides also track the insulin-resistance shift	Apolipoprotein B, the count of atherogenic particles. Conventional laboratories flag ApoB only above 90–130 mg/dL and triglycerides only above 150 mg/dL, well above the functional targets. Fasting 10–12 hours; ApoB is more informative than low-density lipoprotein cholesterol when triglycerides are shifting
Thyroid-stimulating hormone and free thyroxine	Thyroid-stimulating hormone 0.5–2.0 mIU/L; free thyroxine in the upper half of range	Growth hormone increases peripheral thyroid hormone conversion and can unmask marginal central hypothyroidism	Morning draw before any thyroid medication. Conventional thyroid-stimulating hormone reference extends to 4.5 mIU/L, well above the functional target
Morning cortisol	10–15 µg/dL at 8 a.m.	Tests directly whether the compound’s selectivity claim is holding in this individual under chronic use	Drawn between 7 and 9 a.m. because of the diurnal rhythm. The conventional morning reference range runs to roughly 6–23 µg/dL, so values in its upper half read as normal while sitting well above the functional target. Best paired with dehydroepiandrosterone sulfate to interpret adrenal output as a whole
Prolactin	Below 15 ng/mL in men; below 20 ng/mL in women	Second check on pituitary selectivity, since related peptides raise it	Conventional reference ranges extend to about 20 ng/mL in men and 25 ng/mL in women, above the functional targets. Morning draw, avoiding nipple stimulation and strenuous exercise in the preceding 24 hours, both of which elevate it transiently
Prostate-specific antigen (men aged 40 and over)	Below 1.0 ng/mL at age 40–49; below 2.5 ng/mL thereafter, with velocity below 0.35 ng/mL per year	Screens the tissue most plausibly responsive to IGF-1 elevation	Prostate-specific antigen, a blood marker of prostate activity. The conventional referral threshold is 4.0 ng/mL, far above the functional targets. Ejaculation and cycling are avoided for 48 hours before the draw. Rate of change matters more than a single value
Complete blood count and complete metabolic panel	Within reference range	Baseline organ function; growth hormone axis stimulation affects renal sodium handling	Fasting, same draw as the metabolic markers. Sodium and estimated glomerular filtration rate carry the fluid-retention signal
Blood pressure	Below 120/80 mmHg	Fluid retention from growth hormone raises blood pressure before visible swelling appears	Home measurement, seated, morning and evening, averaged over a week rather than a single clinic reading
Body composition by DXA	Individual trajectory: rising lean mass with stable or falling fat mass	The endpoint the intervention is actually taken for, and the only way to distinguish lean gain from fluid and fat	Dual-energy X-ray absorptiometry. Baseline and at 6 months at minimum; same machine and similar hydration state each time, since fluid retention inflates apparent lean mass

Qualitative markers matter here because the objective endpoints move slowly and the earliest warning signs are entirely subjective. The following are tracked as a simple daily or weekly rating alongside the laboratory panel:

Sleep depth and continuity: subjective restfulness on waking, number of awakenings, and — where available — wearable-measured deep sleep duration
Morning recovery and readiness: perceived soreness and readiness to train relative to the same training load before starting
Appetite and hunger timing: whether hunger has increased, and particularly whether evening or nocturnal hunger has appeared, since this is the clearest signal of ghrelin-receptor activity
Hand and finger sensation: any numbness, tingling or morning stiffness, which is the earliest sign of excess growth hormone axis stimulation and warrants dose reduction
Peripheral swelling: ring and shoe fit, ankle puffiness, and facial puffiness on waking
Joint comfort: new or worsening aching in knees, hips, shoulders or hands
Energy and cognitive clarity: daytime alertness and concentration, which respond to sleep quality changes before body composition moves
Skin, hair and nail quality: commonly reported subjectively and consistent with growth hormone’s effect on skin thickness in controlled work

Success at 12 weeks is best defined as a measurable rise in IGF-1 that remains inside the age-adjusted reference range, unchanged or improved fasting glucose and insulin, improved sleep and recovery ratings, and the absence of swelling, joint or hand symptoms. Any of those laboratory markers moving the wrong way constitutes a failed trial regardless of how the subjective markers read.

Emerging Research

Ongoing registered study: The Trifecta Research Study (NCT07717866) is a prospective cohort study in 52 special operations forces combat veterans, sponsored by Axial Therapeutic Research, evaluating a sequence of interventions for post-traumatic stress and traumatic brain injury-related cognitive symptoms. Ipamorelin is included within the “physiological supplementation” arm alongside testosterone, anastrozole, gonadorelin and fish oil. Primary completion was February 2026 with estimated completion in November 2026. Because ipamorelin is bundled with several other agents, the design cannot isolate its contribution — but it is the only registered study currently including the compound.
Unreported Phase 2 program: The 320-participant study of ipamorelin for recovery of gastrointestinal function (NCT01280344) completed in June 2013 and has never posted results, as has the earlier 117-participant study (NCT00672074) whose findings were published separately. The absence of posted results from the larger study, combined with programme termination, is the single most informative unpublished dataset on this compound, and its release would materially change the evidence picture in either direction.
Counter-evidence — receptor blockade in aging: Evidence that could weaken the case comes from aging male mice, where researchers found that deleting GHS-R1a, or inhibiting it pharmacologically with PF-5190457, improved running endurance, reduced muscle fatigue, preserved mitochondrial DNA and citrate synthase (an enzyme of the cellular energy cycle whose activity tracks how much mitochondrial machinery a muscle retains), and increased mitophagy, while overall lifespan was unchanged (Kerr et al., 2026). If this replicates and translates, chronic agonism of the same receptor for musculoskeletal aging would need substantial re-justification.
Supporting evidence — cachexia and sarcopenia: Evidence that could strengthen the case comes from wasting states, where ghrelin-receptor agonists retain a genuine clinical rationale and anamorelin has an established development programme; ipamorelin and anamorelin both inhibited cisplatin-induced weight loss in ferrets (Lu et al., 2024). Extension of ghrelin-agonist trials from cancer cachexia into age-related sarcopenia would be the most plausible route by which ipamorelin’s class acquires the outcome data it currently lacks.
Growth hormone and longevity tension: The strongest counter-argument to the intervention’s premise is comparative and genetic rather than clinical: growth hormone receptor-deficient humans and growth hormone-deficient mouse strains show delayed age-related disease and, in animals, extended lifespan (Aguiar-Oliveira & Bartke, 2019). Whether short pulsatile elevation carries the same liability as chronic elevation is unresolved and is the question with the greatest capacity to change how this compound is viewed.
Regulatory trajectory for compounded peptides: FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides in July 2026 and is scheduled to review five more before the end of February 2027 (FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know). Ipamorelin is on neither list, having already been considered and rejected by the same committee in October 2024. Whether it is re-nominated and reconsidered determines whether a quality-controlled supply becomes possible at all, which is currently a larger practical constraint on its use than the state of the efficacy evidence.
Contemporary clinical syntheses: Three 2026 reviews now frame how clinicians encounter this compound: a sports-medicine review of approved and unapproved peptides (Mendias & Awan, 2026), an endocrinology review proposing an assessment algorithm for patients self-administering growth hormone axis peptides (Dominikowski et al., 2026), and a gerontology review of peptide therapeutics for healthy aging (Mavrych et al., 2026). All three reach the same conclusion — mechanistically interesting, clinically unvalidated — and all three note that self-administration has outpaced evidence by a wide margin.

Conclusion

Ipamorelin is a synthetic five-amino-acid peptide that prompts the pituitary gland to release a short burst of growth hormone. Its distinguishing feature, established in early laboratory and animal work, is that it does this without the rise in stress hormones that the older compounds in its family produce. That much is reasonably well established. Almost everything beyond it is not. Human study of ipamorelin stopped after brief hospital use for a digestive problem, and no trial has measured whether it changes muscle, fat, bone, skin, sleep, recovery, or any outcome tied to how long or how well people live. Expectations about those outcomes are borrowed from related drugs and from growth hormone itself, where controlled work in healthy older people found modest shifts in body composition alongside fluid retention, joint pain, nerve compression at the wrist, and worsening blood sugar. Working against the premise is a large body of aging biology in which reduced growth-hormone signalling, not more of it, tracks with longer life. Practical obstacles are severe: no lawful pharmaceutical supply exists in the United States, seized and gray-market material has repeatedly proven to be a slightly different molecule than labeled, and the compound is banned in competitive sport at all times. The science underlying it came from the company that developed it, and most of today’s enthusiastic writing comes from clinics, pharmacies, and vendors that profit from its sale.

Top - Benefits - Risks - Protocol

Ipamorelin for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Acute, Dose-Dependent Growth Hormone Release

Medium 🟩 🟩

Endocrine Selectivity Relative to Older Growth Hormone-Releasing Peptides ⚠️ Conflicted

Low 🟩

Gain in Fat-Free Mass Through Sustained Growth Hormone Axis Stimulation

Deeper Slow-Wave and Rapid Eye Movement Sleep

Bone Formation and Protection Against Steroid-Induced Bone and Muscle Loss

Faster Return of Gut Motility After Abdominal Surgery ⚠️ Conflicted

Speculative 🟨

Reduction in Body Fat ⚠️ Conflicted

Connective Tissue Repair and Injury Recovery

Reduced Visceral Pain Sensitivity

Preservation of Body Weight During Chemotherapy

Improved Skin Thickness and Collagen Quality

Enhanced Immune Function

Improved Mental Clarity, Mood, Energy and Libido

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Absence of Long-Term Human Safety Data

Unregulated Supply with Documented Product Substitution

Anti-Doping Sanction in Competitive Sport

Medium 🟥 🟥

Insulin Resistance and Rising Fasting Glucose

Fluid Retention, Joint Pain and Nerve Compression

Increased Appetite, Fat Gain and Weight Gain

Cortisol Elevation Under Sustained Receptor Stimulation ⚠️ Conflicted

Low 🟥

Theoretical Promotion of Occult Neoplasia via IGF-1

Injection-Site Reactions and Immunogenicity

Attenuation of the Pituitary Response with Continued Dosing

Common Short-Term Adverse Effects

Speculative 🟨

Insulin Release and Glycemic Instability ⚠️ Conflicted

Acceleration of Aging Biology Through Sustained Growth Hormone and IGF-1 Signalling

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion